The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
D000284:Administration, Oral; D000818:Animals; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000494:pharmacology; D001565:Benzoates / Q000009:adverse effects; D001803:Blood Transfusion; D001835:Body Weight / Q000187:drug effects; D002118:Calcium / Q000652:urine; D002264:Carboxylic Acids / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D002396:Catechols / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D002614:Chelating Agents / Q000009:adverse effects; D003300:Copper / Q000652:urine; D003676:Deferoxamine / Q000008:administration & dosage / Q000494:pharmacology; D004195:Disease Models, Animal; D005243:Feces / Q000032:analysis; D006432:Hemochromatosis / Q000652:urine; D006900:Hydroxylation; D007274:Injections, Intraperitoneal; D007501:Iron / Q000032:analysis / Q000652:urine; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D007504:Iron Radioisotopes; D007928:Lethal Dose 50; D008274:Magnesium / Q000652:urine; D051379:Mice; D008815:Mice, Inbred Strains; D051381:Rats; D015032:Zinc / Q000652:urine
D001565:Benzoates; D002264:Carboxylic Acids; D002396:Catechols; D002614:Chelating Agents; D007502:Iron Chelating Agents; D007504:Iron Radioisotopes; D003300:Copper; D007501:Iron; D008274:Magnesium; D003676:Deferoxamine; D015032:Zinc; D001205:Ascorbic Acid; D002118:Calcium